Home Newsfeeds Jefferies Downgrades CytomX Therapeutics to Hold, Lowers Price Target to $2

Jefferies Downgrades CytomX Therapeutics to Hold, Lowers Price Target to $2

Jefferies analyst Roger Song downgrades CytomX Therapeutics (NASDAQ:CTMX) from Buy to Hold and lowers the price target from $12 to $2.

byBenzinga Newsdesk

July 7, 2022

1 minute read

Jefferies analyst Roger Song downgrades CytomX Therapeutics (NASDAQ:CTMX) from Buy to Hold and lowers the price target from $12 to $2.

News

Cue Health Launches Pharmacy Offering To Empower Individuals To Manage Common Health And Wellness Needs From Home

By Happy Mohamed

May 8, 9:16 AM

Cue now offers over-the-counter and prescription medications for sexual health, birth control, hair loss, and more Cue Health ("Cue") (NASDAQ:HLTH), a healthcare technology company, today announced an

HLTH

Here’s How Much You Would Have Made Owning NVIDIA Stock In The Last 15 Years

By Benzinga Insights

September 16, 11:08 AM

NVIDIA (NASDAQ:NVDA) has outperformed the market over the past 15 years by 13.18% on an annualized basis producing an average annual return of 19.58%. Currently, NVIDIA has a market capitalization of $321.63 billion.

NVDA

News

MDU Resources Expects Q2 Spinoff Of Knife River; Strategic Review Of MDU Construction Services Group Underway

By Michael Horton

December 15, 5:28 PM

MDU Resources Group, Inc. (NYSE:MDU) on Wednesday submitted a confidential draft registration statement on Form 10 with the U.S. Securities and Exchange Commission in connection with the planned spinoff of its

MDU